A ANANDA Scientific Announces FDA Approval of Investigational New Drug for Clinical Institution Aimed at Treatment of Social Phobia

NEW YORK & GREENWOOD VILLAGE, Colorado, November 30, 2022–(BUSINESS WIRE)–To ANANDA Scientific Inc., an investigational biopharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for use of an investigational new drug in a clinical institution testing or Nantheia™ A1002N5San investigational drug that uses canabidiol (CBD) in its administration technology Liquid Structure™ patented by ANANDA as a possible treatment for a Social phobia. TO National Center for Complimentary and Integrative Health (HCCIH, uma divisão do NIH) is a grant that will be made at NYU Grossman School of Medicine. (Identification from Clinical Trials.gov: NCT05571592)

This press release includes multimedia content. See or full press release here: https://www.businesswire.com/news/home/20221129005227/pt/

(Photo: Business Wire)

The lead investigators of the investigation are Naomi Simon, MD, MSc., professor of psychiatry and director of the Anxiety, Stress and Prolonged Grief program at NYU Grossman School of Medicine, and Esther Blessing, MD, PhD, adjunct professor of psychiatry at the NYU Grossman School of Medicine. This duplo-cego placebo controlled test will be analysed Nantheia™ A1002N5S compared to placebo over a 21-day treatment period. Early preventative measures include altering anxiety elicited by the Trier Social Stress Test (TSST) and impacting neuroimaging biomarker.

“We’re content with the progress given this important study to develop new treatments based on evidence for social phobia, an alarming and poorly aborted condition,” he says. Dra. Simon.

Para to Dra. Blessing, “it is incredible the progress made with clinical tests that are based on pre-clinical results animating in relation to CBD as a treatment for anxiety disorders”.

“É um prazer poder trabalhar novamente com a Dra. Simon ea Dra. Blessing nesse IMPORTANT ensaio que poderá afetar a vida de várias pessoas”, destaca Sohail R. Zaidi, CEO of ANANDA. “Esperamos novos avanços no uso do nosso medicamento investigacional, o Nantheia A1002N5S evidence of these significant physicians is pending.”


A ANANDA is a major biopharmaceutical company with a focus on fish, which is a pioneer in high-quality clinical studies that validate therapeutic evidence, such as Post-traumatic Stress Relief, Radiculopathy, Anxiety and Caused Transtornos per opioid use (Mt. Sinai and UCLA). The company uses a patented administration technology, (licensed by Lyotropic Delivery Systems (LDS) Ltd, in Jerusalem, Israel) to develop substâncias derivadas de planta e canabinóides biodisponíveis, solúveis in água e com life útil estável. Furthermore, they focus on producing high quality and effective pharmaceutical products.

The text in the original language of this announcement is the official official authorised. Because translations are only forane as a facility and must refer to an original non-idiomatic text, which is a single version of the text that has legal effect.

View the original version at businesswire.com: https://www.businesswire.com/news/home/20221129005227/pt/


Public Relations from ANANDA Scientific | Christopher Moore | 813 326 4265 | media@anandascientific.com

Leave a Reply

Your email address will not be published. Required fields are marked *